BR112022002029A2 - Uso de sepiapterina e seus metabólitos para tratar exposição à radiação - Google Patents
Uso de sepiapterina e seus metabólitos para tratar exposição à radiaçãoInfo
- Publication number
- BR112022002029A2 BR112022002029A2 BR112022002029A BR112022002029A BR112022002029A2 BR 112022002029 A2 BR112022002029 A2 BR 112022002029A2 BR 112022002029 A BR112022002029 A BR 112022002029A BR 112022002029 A BR112022002029 A BR 112022002029A BR 112022002029 A2 BR112022002029 A2 BR 112022002029A2
- Authority
- BR
- Brazil
- Prior art keywords
- sepiapterin
- radiation exposure
- metabolites
- treat radiation
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
uso de sepiapterina e seus metabólitos para tratar exposição à radiação. a presente invenção refere-se a métodos para tratar a exposição à radiação em um indivíduo através da administração de sepiapterina, tetra-hidrobiopterina ou di-hidrobiopterina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882937P | 2019-08-05 | 2019-08-05 | |
PCT/US2020/045026 WO2021026247A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022002029A2 true BR112022002029A2 (pt) | 2022-06-07 |
Family
ID=72148243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022002029A BR112022002029A2 (pt) | 2019-08-05 | 2020-08-05 | Uso de sepiapterina e seus metabólitos para tratar exposição à radiação |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220273661A1 (pt) |
EP (1) | EP4009978A1 (pt) |
JP (1) | JP2022543655A (pt) |
CN (1) | CN114555090A (pt) |
AU (1) | AU2020324435A1 (pt) |
BR (1) | BR112022002029A2 (pt) |
CA (1) | CA3146477A1 (pt) |
IL (1) | IL290321A (pt) |
MX (1) | MX2022001535A (pt) |
WO (1) | WO2021026247A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
JP2020532535A (ja) | 2017-09-01 | 2020-11-12 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
AU2019277382A1 (en) | 2018-05-30 | 2021-01-21 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
TWI359019B (en) * | 2006-08-14 | 2012-03-01 | Merck Eprova Ag | Use of folates for the prevention and treatment of |
CA3043499A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
JP2020532535A (ja) | 2017-09-01 | 2020-11-12 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
CN112543758A (zh) | 2018-05-30 | 2021-03-23 | Ptc医疗Mp公司 | 墨蝶呤的药学上可接受的盐 |
CN110354133A (zh) * | 2019-08-26 | 2019-10-22 | 鞍山市肿瘤医院 | 四氢生物蝶呤的应用及药物 |
-
2020
- 2020-08-05 JP JP2022507561A patent/JP2022543655A/ja active Pending
- 2020-08-05 CA CA3146477A patent/CA3146477A1/en active Pending
- 2020-08-05 BR BR112022002029A patent/BR112022002029A2/pt unknown
- 2020-08-05 MX MX2022001535A patent/MX2022001535A/es unknown
- 2020-08-05 CN CN202080069308.5A patent/CN114555090A/zh active Pending
- 2020-08-05 EP EP20758407.9A patent/EP4009978A1/en active Pending
- 2020-08-05 US US17/631,995 patent/US20220273661A1/en active Pending
- 2020-08-05 WO PCT/US2020/045026 patent/WO2021026247A1/en active Application Filing
- 2020-08-05 AU AU2020324435A patent/AU2020324435A1/en active Pending
-
2022
- 2022-02-03 IL IL290321A patent/IL290321A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020324435A1 (en) | 2022-02-24 |
CN114555090A (zh) | 2022-05-27 |
MX2022001535A (es) | 2022-03-04 |
EP4009978A1 (en) | 2022-06-15 |
CA3146477A1 (en) | 2021-02-11 |
WO2021026247A1 (en) | 2021-02-11 |
US20220273661A1 (en) | 2022-09-01 |
JP2022543655A (ja) | 2022-10-13 |
IL290321A (en) | 2022-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022002029A2 (pt) | Uso de sepiapterina e seus metabólitos para tratar exposição à radiação | |
CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
BR112020003865A8 (pt) | Composições farmacêuticas compreendendo sepiapterina e seus usos | |
BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
BR112017001162A2 (pt) | métodos para tratar paramixovírus | |
BR112015018094A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
BR112015018087A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
BR112015018089A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
BR112014011925A2 (pt) | mutações no receptor notch humano e seu uso | |
BR112021008873A8 (pt) | Formulação | |
BR112017018160A2 (pt) | uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
BR112021016833A2 (pt) | Compostos com atividade indutora de ferroptose e métodos de seu uso | |
BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
BR112015027474A8 (pt) | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. | |
CO2020014599A2 (es) | Métodos para tratar cáncer | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
BR112019016839A2 (pt) | tratamentos de combinação que compreendem a administração de 1h-pirazolo[4,3-b] piridinas | |
CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
BR112019025611A2 (pt) | Derivados de xantina substituídos |